Market capitalization | $1.30b |
Enterprise Value | $1.62b |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 5.83 |
P/S ratio (TTM) P/S ratio | 4.65 |
P/B ratio (TTM) P/B ratio | 2.97 |
Revenue growth (TTM) Revenue growth | -48.78% |
Revenue (TTM) Revenue | $278.59m |
As a Free StocksGuide user, you can view scores for all 6,908 stocks worldwide.
15 Analysts have issued a Maravai LifeSciences forecast:
15 Analysts have issued a Maravai LifeSciences forecast:
Dec '23 |
+/-
%
|
||
Net Profit | -119 -119 |
154%
154%
|
|
Depreciation and Amortization | 49 49 |
28%
28%
|
|
Stock Compensation | 35 35 |
85%
85%
|
|
Operating Cash Flow | 126 126 |
76%
76%
|
|
Investments | 66 66 |
284%
284%
|
|
Dividend Paid | - - |
-
|
|
Free Cash Flow | 61 61 |
88%
88%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Maravai Lifesciences Holdings, Inc. operates as an investment holding company. It develops biopharmaceuticals. The company is headquartered in San Diego, CA.
Head office | United States |
CEO | William Martin |
Employees | 650 |
Founded | 2014 |
Website | www.maravai.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.